

Northern Health Authority Annual Antibigram 2022*

Northern Health Authority Gram Negative Organisms % Susceptible	# of isolates	Greater than or equal to 80% susceptibility = GOOD CHOICE						Less than 80% susceptibility = POOR CHOICE								
		Amoxicillin/ Clavulanate	Ampicillin	Piperacillin/ Tazobactam	Cefazolin	Cefuroxime	Cefixime	Cefotaxime or Ceftriaxone	Ceftazidime	Meropenem	Gentamicin	Tobramycin	TMP/SMX	Ciprofloxacin	Moxifloxacin	Nitrofurantoin ^U
<i>Escherichia coli</i>	4748	85	65	94	88	-	92	94	-	100	95	96	85	87	-	97
<i>Citrobacter species</i>	149	R	R	R	R	-	R	R	-	100	97	98	95	97	-	88
<i>Enterobacter cloacae</i>	271	R	R	-	R	R	-	-	-	100	99	99	93	97	-	R
<i>Klebsiella aerogenes</i> ^A	62	R	R	-	R	R	-	-	-	100	100	100	98	97	-	R
<i>Klebsiella oxytoca</i>	172	95	R	96	49	-	97	100	-	100	99	99	97	99	-	86
<i>Klebsiella pneumoniae</i>	497	95	R	96	93	-	97	97	-	99	98	98	95	96	-	33
<i>Morganella morganii</i>	66	R	R	-	R	R	-	-	-	100	92	94	86	86	-	R
<i>Proteus mirabilis</i>	242	97	76	99	79	-	95	98	-	100	94	97	92	95	-	R
<i>Serratia marcescens</i>	43	R	R	-	R	R	-	-	-	100	98	98	98	95	-	R
<i>Pseudomonas aeruginosa</i>	339	R	R	90	R	R	R	R					R	84	-	-
<i>Haemophilus influenzae</i> **	25	100	80	-	-	100	-	100	-	-	-	-	79	-	100	-
<i>Stenotrophomonas maltophilia</i> **	29	-	R	-	R	-	-	R	-	R	R	R	90	-	-	R

Notes Percent susceptible for each organism/antimicrobial combination was generated by including the first isolate of that organism encountered on a given patient.
MRSA incidence = 22% (proportion of total clinical isolates of *S. aureus* that are MRSA)

Legend

- Drug not tested or indicated
- \$ AST method not validated for this organism/antibiotic combination
- U Urinary tract infections only
- A Extrapolated from Cloxacillin
- B Extrapolated from Ampicillin
- C Extrapolated from Penicillin
- ^ *Klebsiella aerogenes*, formerly known as *Enterobacter aerogenes*
- † Total *Staphylococcus aureus* isolates (includes MSSA and MRSA)
- ‡ Represents clinical isolates - excludes colonization/screens
- R Intrinsic resistance
- 2 non-meningitis
- 3 meningitis
- ** Organisms with less than 30 isolates have decreased statistical validity

*Prepared by Ally King, Microbiology Quality Resource Technologist, January 2022 based on 2021 cumulative AST data from Jan. 1 2021 to Dec. 31 2021,
As per CLSI document M39-A4 Analysis and presentation of cumulative antimicrobial susceptibility tests data – approved guideline – 4th edition



northern health
the northern way of caring

10-201-6002 (IND Rev. 05/22)

Northern Health Authority Annual Antibigram 2022*

Northern Health Authority Gram Positive Organisms % Susceptible	Greater than or equal to 80% susceptibility = GOOD CHOICE							Less than 80% susceptibility = POOR CHOICE									
	# of isolates	Amoxicillin	Ampicillin	Cloxacillin	Penicillin	Cefazolin ^A	Cefotaxime or Ceftriaxone	Erythromycin	Clindamycin	Ciprofloxacin	Moxifloxacin	Gent Synergy	TMP-SMX	Tetracycline	Nitrofurantoin ^U	Vancomycin	Linezolid
<i>Staphylococcus aureus</i> †	1890	-	-	77	-	77	-	75	85	-	-	-	93	96	-	100	-
<i>S. aureus</i> (MRSA)‡	423	R	R	R	-	R	R	R	84	-	-	-	89	90	-	100	100
<i>Staphylococcus epidermidis</i>	180	-	-	56	-	56	-	53	75	-	-	-	77	87	-	100	-
<i>Staphylococcus lugdunensis</i>	80	-	-	95	-	95	-	79	93	-	-	-	100	99	-	100	-
<i>Enterococcus faecalis</i>	653	100 ^B	100	R	-	-	R	R	R	88	-	86	-	-	99	99	-
<i>Enterococcus faecium</i>	96	R	R	R	-	-	R	R	R	12	-	82	-	-	-	49‡	99
Group A Streptococcus	521	100 ^C	100 ^C	-	100	-	100 ^{\$}	82	82	-	-	-	R	-	-	100	-
Group B Streptococcus	458	100 ^C	100	-	99	-	100 ^{\$}	59	61	-	-	-	R	-	-	100	-
Group C & G Streptococcus	209	100 ^C	100 ^C	-	100	-	100 ^{\$}	80	83	-	-	-	R	-	-	98	-
<i>Streptococcus pneumoniae</i>	45	100	-	-	100 ² 64 ³	-	100 ² 89 ³	78	-	-	100	-	78	-	-	100	-

Notes Percent susceptible for each organism/antimicrobial combination was generated by including the first isolate of that organism encountered on a given patient. MRSA incidence = 22% (proportion of total clinical isolates of *S. aureus* that are MRSA)

Legend

- Drug not tested or indicated
- \$ AST method not validated for this organism/antibiotic combination
- U U Urinary tract infections only
- A Extrapolated from Cloxacillin
- B Extrapolated from Ampicillin
- C Extrapolated from Penicillin
- † Total *Staphylococcus aureus* isolates (includes MSSA and MRSA)
- ‡ Represents clinical isolates - excludes colonization/screens
- R Intrinsic resistance
- 2 non-meningitis
- 3 meningitis

*Prepared by Ally King, Microbiology Quality Resource Technologist, January 2022 based on 2021 cumulative AST data from Jan. 1 2021 to Dec. 31 2021, As per CLSI document M39-A4 Analysis and presentation of cumulative antimicrobial susceptibility tests data – approved guideline – 4th edition